



Review

Early Life Oxidative Stress and Long-Lasting Cardiovascular Effects on Offspring Conceived by Assisted Reproductive Technologies: A Review

Huixia Yang ¹ , Christina Kuhn ^{1,2}, Thomas Kolben ¹ , Zhi Ma ¹, Peng Lin ¹, Sven Mahner ¹, Udo Jeschke ^{1,2,*}  and Viktoria von Schönfeldt ¹

¹ Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany; huixia.yang@med.uni-muenchen.de (H.Y.); christina.kuhn@med.uni-muenchen.de (C.K.); thomas.kolben@med.uni-muenchen.de (T.K.); zhi.ma@med.uni-muenchen.de (Z.M.); lin.peng@med.uni-muenchen.de (P.L.); sven.mahner@med.uni-muenchen.de (S.M.); viktoria.schoenfeldt@med.uni-muenchen.de (V.v.S.)

² Department of Obstetrics and Gynecology, University Hospital Augsburg, 86156 Augsburg, Germany

* Correspondence: udo.jeschke@med.uni-muenchen.de; Tel.: +49-(0)821-400-165505

Received: 29 June 2020; Accepted: 20 July 2020; Published: 22 July 2020



Abstract: Assisted reproductive technology (ART) has rapidly developed and is now widely practised worldwide. Both the characteristics of ART (handling gametes/embryos in vitro) and the infertility backgrounds of ART parents (such as infertility diseases and unfavourable lifestyles or diets) could cause increased oxidative stress (OS) that may exert adverse influences on gametogenesis, fertilisation, and foetation, even causing a long-lasting influence on the offspring. For these reasons, the safety of ART needs to be closely examined. In this review, from an ART safety standpoint, the origins of OS are reviewed, and the long-lasting cardiovascular effects and potential mechanisms of OS on the offspring are discussed.

Keywords: oxidative stress; long-lasting; cardiovascular; assisted reproductive technologies; offspring

1. Introduction

The use of assisted reproductive technology (ART) began in 1978. Since then, ART has been widely used worldwide [1]. More than eight million human babies are estimated to have been conceived through ART [2], and the annual increase in this number is estimated to average at 9.1% per year [1]. ART is developing rapidly, and now includes techniques such as intra-uterine insemination (IUI), in vitro fertilisation (IVF), intracytoplasmic sperm injection (ICSI), accompanied by controlled ovarian hyperstimulation (COH), oocyte retrieval, embryo culture, and embryo transfer, with or without pre-implantation genetic diagnosis or screening (PGD or PGS), gametes or embryos freezing and thawing, surgical sperm retrieval (SSR), and assisted hatching [3,4].

Despite all advances, it is unavoidable that gametes or embryos are handled in vitro. Because ART occurs at the preimplantation period when gametes or embryos are highly sensitive and experience developmental plasticity, the environmental stimuli may alter the embryonic developmental trajectory. According to the 'developmental origins of adult disease' (DOHaD) hypothesis [5], environmental exposures in early life can exert a long-lasting influence on health and lead to adult-onset chronic non-communicable diseases (NCDs) such as hypertension [6], cardiovascular diseases (CVDs) [7], and type 2 diabetes mellitus (T2DM) [8]. ART can be regarded as an extreme 'exposure', despite the fact that conclusions of ART safety studies are conflicting, the possible adverse effects have been linked to birth defects [9], epigenetic diseases [10], dysfunction of various body systems (e.g., cardiovascular, metabolic, and neurological systems) [11], and paediatric neoplasms (e.g., leukaemia and Hodgkin's

lymphoma) [12,13]. The observed long-term outcomes of ART, including cardiometabolic and neurological NCDs, are consistent with the DOHaD model [14].

Oxidative stress (OS) is related to an excess of reactive oxygen species (ROS) and a decrease in antioxidant enzymes. This concept was established by Helmut in 1985 [15]. Excess ROS has been proposed to cause severe damage during embryonic development [16], especially in the cardiovascular system, because it is one of the first functional systems to develop. In the ART area, studies on OS have focused on infertile men and their sperm [17,18]. It is now well established that the main cause of male infertility is OS, which can damage sperm DNA, influencing the health of the offspring [19]. Studies have also revealed that OS plays a vital role in ART outcomes. A study found that a reduction in OS improved ART outcomes [20]. Various factors associated with ROS production in an ART setting have been investigated, and the antioxidant strategy in an ART setting has also been explored [20,21]. Several animal models have been applied to study the effect and associated mechanisms of OS on ART offspring [22]. Nevertheless, to the best of our knowledge, no human epidemiological studies have looked at the effect of OS on ART offspring. On the one hand, the health outcome-related follow-up information of ART offspring in the available databases are insufficiently detailed and are even lacking. On the other hand, no databases have recorded the OS status in an ART setting for ART offspring. In fact, in other medical areas, there have been countless studies on OS/ROS, most of which are focused on the negative effects of excessive ROS/OS. Excessive ROS/OS has been implicated in over 100 diseases [23] (e.g., diabetes mellitus [24], CVDs [25], and neurodegenerative diseases [26]), also playing an important role in the pathogenicity of ageing [27].

In this review, from the ART point of view, we describe the origins of OS, provide a timely synthesis of the current evidence on the long-lasting cardiovascular effects of ART-associated OS, and discuss the potential underlying mechanisms. We expect that our review will inform future OS-associated research in the ART area as well as propose suggestions for preventing adverse health outcomes in ART offspring.

2. Origins of OS

2.1. Paternally Derived OS

OS has been linked to a variety of male fertility complications, including leukocytospermia [28], varicocele [29], cryptorchidism [30], spermatic cord torsion [31], male accessory gland infections (MAGI) [32], advanced age [33], obesity [34], diabetes [35], and autoimmune disorders [33]. Infertile men are more likely to possess excessive levels of ROS compared to fertile men [36], which has been identified as one of the few defined aetiologies for male infertility [37]. Recently, male oxidative stress infertility (MOSI) has been proposed to describe infertile men with OS and abnormal semen characteristics. This term includes many patients previously classified as having male idiopathic infertility [38].

In the male genital tract, in addition to the ROS generated from sperm cells [39], other cells may also produce ROS. Among them, leukocytes can produce ROS at levels 1000 times higher than that of sperm at capacitation [40] and may contribute to OS [41]. Further compounding this issue, the plasma membrane of sperm cells contains large quantities of polyunsaturated fatty acids (PUFAs), making them particularly susceptible to elevated ROS levels during OS [42]. OS can also negatively influence other sperm components (i.e., nucleic acids and proteins), inducing sperm DNA fragmentation (SDF) and low sperm motility [43]. Furthermore, compared with somatic cells, there is a lack of cytoplasm and poorer antioxidant capacity in mature spermatozoa, thereby rendering it more vulnerable to OS [44]. Nevertheless, it is entirely possible for sperm suffering from oxidative DNA damage to fertilise an oocyte and thus possibly exert adverse effects on the offspring [45], especially in the context of ICSI [46]. On the other hand, lifestyle and diet factors such as cigarette smoking [47], alcohol abuse [48], psychological stress [49], recreational and illicit drugs use [17,50], malnutrition [51], and excessive physical activity [52]; environmental and occupational exposures such as air pollution [53], radiation [54], heat stress [55], plasticizers (e.g., phthalates) [56], heavy metals (e.g., cadmium) [57],

and pesticide/herbicides [33]; and special treatments such as radiation therapy and chemotherapy have been linked with OS [58,59] (as shown in Figure 1).




Figure 1. This figure shows the origins of paternally derived OS. The origins of OS that could affect fathers and their gametes mainly derive from four causes: male fertility complications, lifestyle/diet, environmental/occupational exposures, and special treatments. OS, oxidative stress; MAGI, male accessory gland infections; MOSI, male oxidative stress infertility.

2.2. Maternally Derived OS

Compared with studies of OS and male sperm, it appears that fewer studies have focused on OS and oocytes/oocyte-cumulus complexes. Nevertheless, it cannot be assumed that this point is less important in oogenesis, fertilisation, pregnancy, and production of healthy offspring. After all, the earliest determinant of life potential is the oocyte. In the female reproductive system, the uterine environment, fallopian tubes, and follicular fluid are the main sources generating ROS [60–62]. Normal levels of ROS are responsible for pregnancy establishment in IVF cycles, while excess ROS in the follicular fluid can present a substantial threat to successful assisted reproduction [63].

Recent studies have also shown that OS may cause absence of the oocyte meiotic spindle and may be closely associated with low fertilization rates, compromised embryonic quality, and decreased clinical pregnancy rates [64]. In fact, women attending ART units are usually of advanced age and/or have been diagnosed with other diseases (e.g., endometriosis [65], polycystic ovary syndrome (PCOS) [66], hydrosalpinx [67], and obesity [52]). After pregnancy, women who underwent ART have been reported to be affected by higher incidences of several pregnancy complications (e.g., hypertensive disorders of pregnancy (HDP) [68], gestational diabetes mellitus (GDM) [68], intrauterine growth restriction (IUGR) [69], and preterm birth [68]). All these diseases and pregnancy complications are associated with increased OS, which might exert an influence on the offspring's development [70]. Specifically, during the maternal ageing process, significantly increased OS occurs in the ovarian and follicular environment, causing impaired oocyte quality and compromised oocyte meiosis [71]. Similar to men, unfavourable lifestyles and diets, adverse environmental and occupational exposures, and special treatments can also contribute to excessive OS in women [52,70,72–78] (as shown in Figure 2). Different from men, women exert OS on the offspring, not only through the fertilised oocytes, but also through the uterine environment throughout the whole pregnancy.




Figure 2. This figure shows the origins of maternally derived OS. The origins of OS that could affect the mothers, gametes, and their pregnancies mainly derive from five aspects: female fertility complications, lifestyle/diet, environmental/occupational exposures, special treatments and pregnancy complications. PCOS, polycystic ovary syndrome; HDP, hypertensive disorders of pregnancy; GDM, gestational diabetes mellitus; IUGR, intrauterine growth restriction.

2.3. ART-Derived OS

ART requires in vitro manipulations of gametes or embryos in a synthetic culture environment. Due to lack of a natural antioxidant system and factors driving ROS production (Figure 3), it is difficult to maintain pro-oxidant/antioxidant balance in vitro, and the resulting increased OS may have an adverse impact on the embryo/offspring. There are various stimuli of OS in the ART setting, including cryopreservation [79,80], gamete or embryo manipulation [81], visible light [82], pH fluctuations [83], temperature fluctuations [84], fluctuating oxygen tension (Pa, O₂) [85], centrifugation [86], culture media (especially those containing specific substances, e.g., Fe²⁺ and Cu²⁺) [62], and others. For example, in the oviduct and uterus, under certain physiological conditions, gametes or embryos are exposed to O₂ concentrations of 2–8 % [87]. During in vitro manipulations, gametes and embryos have a chance of being exposed to higher O₂ concentrations (e.g., atmospheric O₂ concentrations around 20–21%). The presence of high concentrations of O₂ during the incubation stage can activate a variety of cellular oxidase enzymes. This in turn generates excessive ROS, leading to OS [88]. The excess ROS can impact the biological processes of early embryonic development with potentially long-lasting health effects for the offspring.

Collectively, compared with naturally conceived offspring, ART offspring appear to be more likely to suffer from excessive OS. Meanwhile, it should be noted that most of the OS originating from ART parents (e.g., adverse lifestyles and environmental exposures) and ART per se are preventable. For ART-associated OS, the potential management includes oral antioxidant supplements for ART parents [89] and modifications in ART protocols. These include antioxidant supplements to ART culture media [20,89], antioxidant techniques in semen preparation, reduced oocyte-handling time, and minimal exposure of zygotes to atmospheric oxygen concentrations [20]. The ART-associated antioxidants consist of enzymatic antioxidants (e.g., superoxide dismutase, catalase, and the glutathione system), non-enzymatic antioxidants (e.g., Vitamins E, C, and B9 (folic acid), melatonin, coenzyme Q10, and L-carnitine) and combined antioxidants (e.g., Vitamin E + Vitamin C) [89]. Diets containing antioxidant molecules for ART parents may also provide antioxidant benefits [90].




Figure 3. This figure shows the origins of ART-derived OS. During ART, several factors might lead to elevated OS. ART, assisted reproductive technology.

3. OS-Associated Mechanisms in ART

3.1. Formation of OS

Various stress conditions may contribute to OS with increased production of ROS. ROS (e.g., superoxide ($O_2^{\bullet-}$), hydroperoxyl (HO_2^{\bullet}), hydroxyl (OH^{\bullet}), and peroxy radicals (RO_2^{\bullet}), and hydrogen peroxide (H_2O_2) [91]) are generated from the partial reduction of O_2 to $O_2^{\bullet-}$, which occurs as a result of oxygen's preferential acceptance of one electron at the time of redox reactions [92]. ROS are highly active molecules that are continuously generated by mitochondrial electron transport and enzymes (e.g., nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, xanthine oxidase, and lipoxygenase) [93]. ROS that originate intracellularly can be released extracellularly [94], and play vital roles in modulating the signaling pathways in response to intra- and extra-cellular stimuli [95]. Mitochondria are the primary source of ROS, resulting from its role in energy (i.e., ATP) production via oxidative phosphorylation (OXPHOS) [92]. The major sites of ROS emission in the respiratory chain are complex I and complex III [96]. During IVF, selected spermatozoa and oocytes are combined in a petri dish with the fertilisation medium and are checked for fertilization after several hours' incubation. During this time, ROS can be generated from the oocyte/cumulus cell mass and the spermatozoa, due to the cells' own metabolism, and the levels of ROS production can be elevated due to the lack of a natural antioxidant defence system and various stimuli. Furthermore, during centrifugation, excess ROS can be derived from the spermatozoa because of the absence of antioxidant-rich seminal plasma and the activation of ROS production [20]. In addition, the external environment that surrounds the cells in an ART setting can also induce OS. For example, even though the composition of the commercial culture media changes over time with various suppliers, most contain serum or serum synthetic replacements, vitamins, albumin, and other components (e.g., heavy metal chelators or

buffer). Therefore, the medium itself can be a trigger of OS [97]. Other environmental factors can also contribute to OS as mentioned. In response to various environmental stimuli, cells produce certain mediators and intermediates (mostly ROS) to propagate environmental signals to the cell nucleus, affecting gene regulation and transcription while inducing various phenotypic responses (in the form of inflammation and pathogenesis) [98].

3.2. Epigenetic Modifications Resulting from OS

Epigenetic modifications refer to dynamic and heritable changes in gene expression without DNA sequence changes. These are profoundly involved in OS responses [99] and are regarded as potential mechanisms that influence the developmental origins of CVDs later in adulthood [100]. Maximal epigenetic reprogramming, characterized as 'dynamic', 'extremely sensitive', and 'plastic', occurs during the early stages of life, coinciding with the time that ART procedures take place [101,102]. Both animal studies and follow-up studies of ART children suggest that ART can cause epigenetic perturbation in offspring [10,103], even at the two-cell stage of embryos [104]. It has been proposed that OS during pregnancy may affect the intrauterine foetus and cause cardiovascular dysfunction in later life through epigenetic modifications [105]. Based on these findings, we speculated that ART-associated OS may also influence the offspring through an epigenetic mechanism. In general, ROS can affect epigenetic modifications through both direct and indirect means [106]. For example, OH• can directly lead to the transformation from 5-methylcytosine (5-mC, a form of DNA methylation) to 5-hydroxymethylcytosine (5-hmC, an intermediate in active DNA demethylation [107]) [108], which has been suggested to interfere with DNA methyltransferase 1 (DNMT1), preventing the proper inheritance of methylation patterns, thereby causing indirect CpG sites demethylation [109]. ROS can also indirectly affect epigenetic modifications. For example, H₂O₂-induced OS can impair histone demethylase activity, causing increased global histone methylation of histone H3 lysine 4 (H3K4), histone H3 lysine 27 (H3K27), and histone H3 lysine 9 (H3K9), while H3K4 trimethylation (H3K4me₃) appears to be affected most by OS; global acetylation levels show temporary decreases in response to OS and return to normal levels after long-term OS. The activity of DNA demethylases (ten-eleven-translocation (TET) proteins) can also be compromised by OS, inducing global 5-mC increases and 5-hmC decreases [110]. These epigenetic modifications can then regulate gene expression via changes in chromatin accessibility in response to OS [111]. Kietzmann et al. described an ROS-related epigenetic landscape in cardiovascular systems; we direct interested readers to a detailed review [106]. Furthermore, evidence also suggests an interplay between OS and epidemic modifications [112,113]. For example, the down-regulation of SUV39H1 (a H3K9 histone methyltransferase) facilitates the recruitment of SRC-1 (a histone acetyltransferase) and JMJD2C (also known as KDM4C, a H3K9 histone demethylase) with reduced di/trimethylation and acetylation of H3K9 on the promoter of p66Shc (a key driver of mitochondrial OS and vascular damage [114]), which may ultimately drive OS [115].

3.3. Nrf2-Mediated Anti-OS Signaling Pathway

The redox-sensitive transcriptional factor nuclear factor erythroid 2-related factor 2 (Nrf2, also known as NFE2L2) is a well-characterized 'master regulator' of antioxidant gene expression via its activation of the Nrf2-antioxidant response element (ARE) pathway [116]. Nrf2 dysregulation has been implicated in different aspects of CVDs [117] and multiple types of cancers (e.g., ovarian cancer [118], breast cancer [119], and glioblastoma [120]), while Nrf2 itself has been identified as a promising therapeutic target for these chronic diseases resulting from its role in providing cytoprotection against diverse stress and pathologies [121]. Recent preclinical data have revealed that N-palmitoylethanolamine-oxazoline (PEA-OXA), an antioxidant compound, protects against cardiovascular complication through upregulation of Nrf2 and Nrf2-target genes [122]. Other compounds (e.g., linarin (LIN) [123] and resveratrol (RES) [124]) also provide beneficial effects in myocardial ischemia/reperfusion injury and CVDs by activating Nrf2. In utero, excessive OS can trigger a cascade of molecular events, imperilling the health of offspring [125]. The Nrf2-mediated

OS response is one of the most important cytoprotective mechanisms against OS as it transcribes many antioxidative genes and ROS-scavenging proteins [126] that are not only closely associated with embryo survival in in vitro conditions [127], foetal development in utero, and cardiometabolic health in childhood or later life [128], but also involved in maintaining vascular homeostasis [129]. Given this evidence, it is reasonable to assume that Nrf2-mediated antioxidant signaling pathway may also serve as an important mechanism for OS-induced cardiovascular effects in ART offspring. Under redox homeostasis, Nrf2 is bound to its inhibitor, Kelch-like ECH-associated protein 1 (Keap1), and is located in the cytoplasm, where it facilitates the ubiquitin-mediated degradation of Nrf2. However, during OS, Nrf2 is phosphorylated and released from Keap1 and is translocated and accumulated in the nucleus, where it heterodimerizes with small musculoaponeurotic fibrosarcoma (Maf) proteins, binds to ARE, and transcriptionally upregulates antioxidant gene expression [130]. The representative antioxidant genes regulated by Nrf2 are summarized in Table 1.

Table 1. Antioxidant genes regulated by Nrf2.

Gene	Protein Encoded	Synonyms	Species ¹	Refs
GSH-based antioxidant genes				
<i>GCLC</i>	Glutamate-cysteine ligase catalytic subunit	<i>GCS, GLCL, GLCLC</i>	m, h	[131–133]
<i>GCLM</i>	Glutamate-cysteine ligase modifier subunit	<i>GLCLR</i>	m, h	[131–134]
<i>GGT1</i>	Gamma-glutamyltransferase 1	<i>CD224, D22S672, D22S732, GGT</i>	h	[131]
<i>GLRX</i>	Glutaredoxin	<i>GRX, GRX1</i>	h	[131]
<i>GLS</i>	Glutaminase	<i>GLS1, KIAA0838</i>	h	[131]
<i>GPX1</i>	Glutathione peroxidase 1	-	m	[135,136]
<i>GPX2</i>	Glutathione peroxidase 2	<i>GSHPX-GI</i>	m, h	[131,137–140]
<i>GPX4</i>	Glutathione peroxidase 4	<i>MCSP, PHGPx</i>	m	[131]
<i>GSR</i>	Glutathione-disulfide reductase	-	m, h	[133,134]
<i>GSTA1</i>	Glutathione S-transferase alpha 1	-	m	[131,141–143]
<i>GSTA2</i>	Glutathione S-transferase alpha 2	-	m	[132,142,143]
<i>GSTA3</i>	Glutathione S-transferase alpha 3	-	m	[141–143]
<i>GSTA4</i>	Glutathione S-transferase alpha 4	-	m	[144]
<i>GSTM1</i>	Glutathione S-transferase mu 1	<i>GST1, H-B, MU</i>	m	[131,132,143,144]
<i>GSTM2</i>	Glutathione S-transferase mu 2	<i>GST4</i>	m	[132,143,144]
<i>GSTM3</i>	Glutathione S-transferase mu 3	<i>GST5</i>	m, h	[132,134,143,144]
<i>GSTM4</i>	Glutathione S-transferase mu 4	-	m	[144]
<i>GSTM5</i>	Glutathione S-transferase mu 5	-	m	[145]
<i>GSTM6</i>	Glutathione S-transferase mu 6	-	m	[144]
<i>GSTP1</i>	Glutathione S-transferase pi 1	<i>FAEES3, GST3, GSTP</i>	m	[131]
<i>MGST1</i>	Microsomal glutathione S-transferase 1	<i>GST12, MGST-I</i>	m, h	[131]
<i>MGST2</i>	Microsomal glutathione S-transferase 2	<i>MGST-II</i>	m	[143]
<i>MGST3</i>	Microsomal glutathione S-transferase 3	<i>GST-III</i>	m	[132,143]
<i>SLC6A9</i>	Solute carrier family 6 member 9	<i>GLYT1</i>	m	[131]
<i>SLC7A11</i>	Solute carrier family 7 member 11	<i>xCT</i>	m, h	[131,146]
TXN-based antioxidant genes				
<i>PRDX1</i>	Peroxiredoxin 1	<i>NKEFA, PAGA</i>	m	[131,138,142]
<i>PRDX6</i>	Peroxiredoxin 6	<i>1-Cys, aiPLA2, AOP2, KIAA0106, MGC46173, NSGPx, p29, PRX</i>	h	[131,147]
<i>SRXN1</i>	Sulfiredoxin 1	<i>C20orf139, dJ850E9.2, Npn3, SRX1, YKL086W</i>	m, h	[131]
<i>TXN</i>	Thioredoxin	<i>TRX</i>	m, h	[131,132,135]
<i>TXNRD1</i>	Thioredoxin reductase 1	<i>GRIM-12, Trxr1, TXNR</i>	m, h	[131,135,144]
ATP-binding-based antioxidant genes				
<i>ABCB6</i>	ATP binding cassette subfamily B member 6	<i>EST45597, MTABC3, umat</i>	m, h	[131]
<i>ABCC1</i>	ATP binding cassette subfamily C member 1	<i>GS-X, MRP, MRP1</i>	m, h	[131]
<i>ABCC2</i>	ATP binding cassette subfamily C member 2	<i>CMOAT, cMRP, DJS, MRP2</i>	m, h	[131,141]
<i>ABCC3</i>	ATP binding cassette subfamily C member 3	<i>cMOAT2, EST90757, MLP2, MOAT-D, MRP3</i>	m, h	[131,141,148]
<i>ABCC4</i>	ATP binding cassette subfamily C member 4	<i>EST170205, MOAT-B, MOATB, MRP4</i>	m	[131]
<i>ABCC5</i>	ATP binding cassette subfamily C member 5	<i>EST277145, MOAT-C, MRP5, SMRP</i>	m	[131]
Heme/iron metabolism-associated antioxidant genes				
<i>BLVRA</i>	Biliverdin reductase A	<i>BLVR</i>	h	[131]
<i>BLVRB</i>	Biliverdin reductase B	<i>FLR, SDR43U1</i>	m, h	[131]
<i>FTH1</i>	Ferritin heavy chain 1	<i>FHC, FTH, FTHL6, PIG15, PLIF</i>	m, h	[131]
<i>FTL</i>	Ferritin light chain	<i>MGC71996, NBIA3</i>	m, h	[131]
<i>HMOX1</i>	Heme oxygenase 1	<i>bK286B10, HO-1</i>	m, h	[131,133–135,140,145]

Table 1. Cont.

Gene	Protein Encoded	Synonyms	Species ¹	Refs
UDP glucuronosyltransferase-associated antioxidant genes				
<i>UGT1A1</i>	UDP glucuronosyltransferase family 1 member A1	<i>GNT1, UGT1, UGT1A</i>	h	[131]
<i>UGT1A6</i>	UDP glucuronosyltransferase family 1 member A6	<i>GNT1, HLUGP, UGT1F</i>	m	[138]
<i>UGT2B1</i>	UDP glucuronosyltransferase family 2 member B1	-	m	[141]
<i>UGT2B5</i>	UDP glucuronosyltransferase family 2 member B5	-	m	[132,143]
<i>UGT2B7</i>	UDP glucuronosyltransferase family 2 member B7	<i>UGT2B9</i>	m, h	[131]
Other antioxidant genes				
<i>ADH7</i>	Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	<i>ADH-4</i>	m	[131]
<i>AKR1A1</i>	Aldo-keto reductase family 1 member A1	<i>ALR, DD3</i>	h	[132,143]
<i>AKR1B1</i>	Aldo-keto reductase family 1 member B1	<i>ALDR1, AR</i>	m, h	[131]
<i>AKR1B8</i>	Aldo-keto reductase family 1 member B8	-	m	[142,143]
<i>AKR1C1</i>	Aldo-keto reductase family 1 member C1	<i>DD1, DDH, DDH1, HAKRC, MBAB</i>	h	[131]
<i>ALDH1A1</i>	Aldehyde dehydrogenase 1 family member A1	<i>ALDH1, PUMBI, RALDH1</i>	m	[131]
<i>ALDH3A1</i>	Aldehyde dehydrogenase 3 family member A1	<i>ALDH3</i>	m, h	[131]
<i>ALDH7A1</i>	Aldehyde dehydrogenase 7 family member A1	<i>ATQ1, EPD, PDE</i>	m	[131]
<i>CAT</i>	Catalase	-	m	[137,141]
<i>CBR1</i>	Carbonyl reductase 1	<i>CBR, SDR21C1</i>	h	[131]
<i>CYP1B1</i>	Cytochrome P450 family 1 subfamily B member 1	<i>CP1B, GLC3A</i>	m	[131]
<i>CYP2B9</i>	Cytochrome P450 family 2 subfamily B member 9	-	m	[131]
<i>G6PD</i>	Glucose-6-phosphate dehydrogenase	<i>G6PD1</i>	m, h	[131]
<i>IDH1</i>	Isocitrate dehydrogenase (NADP(+)) 1, cytosolic	-	m	[131]
<i>ME1</i>	Malic enzyme 1	-	m, h	[131]
<i>NQO1</i>	NAD(P)H quinone dehydrogenase 1	<i>DHQU, DIA4, DTD, NMOR1, QRI</i>	m, h	[131,132,134,135,142,143]
<i>PGD</i>	Phosphogluconate dehydrogenase	-	m, h	[131]
<i>PTGR1</i>	Prostaglandin reductase 1	<i>LTB4DH, ZADH3</i>	h	[131]
<i>SOD1</i>	Superoxide dismutase 1	<i>ALS, ALS1, IPOA</i>	m	[141]
<i>SOD2</i>	Superoxide dismutase 2	-	m	[141]
<i>SOD3</i>	Superoxide dismutase 3	<i>EC-SOD</i>	m	[142]
<i>TALDO1</i>	Transaldolase 1	-	m, h	[131]
<i>UGDH</i>	UDP-glucose 6-dehydrogenase	-	h	[131]

¹ The species means the gene has been identified in mouse (m) and/or human (h). Nrf2, nuclear factor erythroid 2-related factor; GSH, glutathione; UDP, uridine diphosphate. The GSH and TXN antioxidant pathways are two important downstream pathways of Nrf2 [117].

Collectively, in the ART area, increased OS is one of the major triggers of early life genetic/epigenetic changes in the offspring. From a preventive point of view, the adverse influence of OS can possibly be reversed through timely appropriate interventions (e.g., medical supplements for ART children and ART parents, chemical modification of ART culture media), opening a window for the potential prevention of adverse long-lasting effects on ART offspring.

4. Long-Lasting Cardiovascular Effects

In the human body, ROS act as a 'double-edged sword', playing a paradoxical role. Normal levels of ROS are important regulators of various transcription factors and signal transduction pathways. Excessive ROS levels can lead to OS, causing damage to cellular components (e.g., proteins, lipids, and DNA), mitochondrial dysfunctions, inhibition of oocyte maturation, delayed embryonic development, and induction of apoptosis in embryos [149]. Several lines of evidence suggest that OS plays a key role in the foetal programming of adulthood CVDs [150–153]. Studies on mammalian offspring suffering from OS (e.g., hypoxia-reoxygenation) during the gestational period reported that these offspring developed endothelial dysfunction [150,151], enhanced myocardial contractility [151], and hypertension [150,152] in adulthood. Foetal programming-induced alterations are transmissible not only throughout life but also in the subsequent generation [22].

From the maternal point of view, advanced maternal age (AMA) [154,155] and OS-increased ART-associated pregnancy complications (e.g., HDP [156,157], GDM [158], IUGR [159], and preterm birth [100]) are frequently associated with cardiovascular dysfunction in the offspring. For example, AMA/HDP/IUGR have been linked with increased blood pressure and/or altered cardiovascular function in offspring [154–156,159], while GDM/preterm birth have been linked with CVDs in offspring [100,158]. Specifically, in a mouse model, it was reported that AMA affects the phenotype of the offspring in a

sex-dependent manner: in young adulthood (four months of age), male (but not female) offspring birthed by aged dams presented reperfusion injury and impaired endothelium-dependent relaxation. In mature adulthood (12 months of age), female offspring showed increased systolic blood pressure, whereas male offspring showed decreased ventricular diastolic function and increased vascular sensitivity to methacholine [154,155].

Because of the relative novelty of ART, the follow-up times of relevant studies remain limited, and the debate as to whether the ART techniques cause long-lasting adverse effects on the offspring remains ongoing. Epidemiological studies on ART children and young adults revealed that the ART offspring presented cardiovascular problems (e.g. congenital heart defect [160] and postnatal dysfunctions of the cardiovascular system [161–164]), despite the fact that one study reported, among 22–35-year-old adults, ART did not correlate with an increase in prevalent cardiovascular risk factors. However, the study population in this study was still in early adulthood and the authors only used non-invasive methods to detect early markers of sub-clinical atherosclerosis; therefore, they did not evaluate the relationships with clinical cardiovascular events (e.g., CVDs) [165]. Several systematic reviews and meta-analyses [166–168] have been performed on the cardiovascular profiles of offspring conceived by ART, with the results revealing mild but statistically significant cardiovascular differences in ART offspring. As Guo et al. concluded, ART-conceived children showed mildly but statistically significantly elevated blood pressure with sub-optimal diastolic function, thicker blood vessels, and lower levels of low-density lipoprotein cholesterol (LDL-C) [167].

Despite the limited data on human ART offspring, subclinical cardiometabolic alterations are detectable. Nevertheless, because CVDs are chronic, adult-onset diseases and significant signs of CVDs require years to develop. ART is relatively new; therefore, the follow-up time of epidemiological studies on ART remains limited (i.e., the first ‘test-tube baby’, Louise Brown, was born in 1978 [169] and was only 42 years old as of 2020). Therefore, it is too early to form a definite conclusion. More long-term (even life-long) follow-up periods are warranted.

5. Limitations and Prospects of Current Studies

Regarding human ART studies such as those studying the influence of OS in a cohort, it is not clear whether ART is the culprit for OS or whether the infertility factors of ART parents play confounding roles. Moreover, the spectrum of ART-offspring demographic confounders (e.g., lifestyles, dietary habits, familial socio-economic status, adverse childhood experiences, as well as other life experiences), rapidly changing ART protocols, and the various types of culture media make such research more complex. To guarantee a detailed multivariate examination of this kind of study, a large sample size may be key to ensuring adjustments for various confounders. A comprehensive record of clinical and laboratory parameters (independent variables) and a prospective longitudinal design are also necessary.

To independently study the influence of ART on offspring, the ART mouse is an excellent model (i.e., there is no background of infertility; pregnancy and juvenile periods are short; and it is possible to appropriately replicate complications in humans [168]). Human embryonic stem cells (hESC) can also serve as a novel *in vitro* model to study the effects of OS on the early embryo [170].

In fact, in human assisted reproduction, both the ART procedure and the infertility backgrounds of ART parents may cause increased OS. Increased OS not only is the reason for patients visiting ART clinics, but it is also the outcome of *in vitro* ART manipulations. Despite increased OS being a prevalent phenomenon in ART, (i) there are no established uniform indicators of OS or standardized cut-off values for ART, ART men, and ART women; (ii) some ART laboratories make no attempt to test for the presence of OS; (iii) neither do the majority of ART clinics analyse their patients’ OS statuses nor pay attention to the clinical causes and sentinel signs of OS, nor do they suggest any changes to OS-related adverse lifestyles or instigate any measures to maintain the redox balance in their patients. Nevertheless, these approaches will not only increase a couple’s chances of natural conception, but will also optimise the efficiency of the ART and the health of ART offspring.

6. Conclusions

OS, which have potentially adverse effects on ART offspring, may derive not only from ART per se but also from the infertility backgrounds of ART parents. OS might exert a long-lasting influences on the offspring's cardiovascular system via epigenetic and genetic alterations (Figure 4).




Figure 4. This figure shows the early-life OS exert long-lasting effects on offspring conceived by ART. ncRNAs, non-coding RNAs; miRNAs, micro-RNAs; lncRNAs, long non-coding RNAs.

Funding: This research received no external funding.

Acknowledgments: Z.M. is supported by the China Scholarship Council (CSC). Z.M. acknowledges the CSC for supporting a visit to Ludwig-Maximilians-University (LMU).

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

ART	Assisted reproductive technology
IUI	Intra-uterine insemination
IVF	In vitro fertilisation
ICSI	Intracytoplasmic sperm injection
COH	Controlled ovarian hyperstimulation
PGD	Pre-implantation genetic diagnosis
PGS	Pre-implantation genetic screening
SSR	Surgical sperm retrieval
DOHaD	Developmental Origins of Adult Disease
NCDs	Non-communicable diseases
CVDs	Cardiovascular diseases
T2DM	Type 2 diabetes mellitus
OS	Oxidative stress
ROS	Reactive oxygen species
MAGI	Male accessory gland infections

MOSI	Male oxidative stress infertility
PUFAs	Polyunsaturated fatty acids
SDF	Sperm DNA fragmentation
PCOS	Polycystic ovary syndrome
HDP	Hypertensive disorders of pregnancy
GDM	Gestational diabetes mellitus
IUGR	Intrauterine growth restriction
O ₂	Oxygen
O ₂ ^{•-}	Superoxide
HO ₂ [•]	Hydroperoxyl
OH [•]	Hydroxyl
RO ₂ [•]	Peroxyl radicals
H ₂ O ₂	Hydrogen peroxide
NADPH	Nicotinamide adenine dinucleotide phosphate
OXPHOS	Oxidative phosphorylation
5-mC	5-methylcytosine
5-hmC	5-hydroxymethylcytosine
DNMT1	DNA methyltransferase 1
H3K4	Histone H3 lysine 4
H3K27	Histone H3 lysine 27
H3K9	Histone H3 lysine 9
H3K4me3	H3K4 trimethylation
TET	Ten-eleven-translocation
Nrf2	Nuclear factor erythroid 2-related factor
ARE	Antioxidant response element
PEA-OXA	N-palmitoylethanolamine-oxazoline
LIN	Linarin
RES	Resveratrol
Keap1	Kelch-like ECH-associated protein 1
Maf	Musculoaponeurotic fibrosarcoma
AMA	Advanced maternal age
LDL-C	Low-density lipoprotein cholesterol
hESC	Human embryonic stem cells

References

1. Dyer, S.; Chambers, G.M.; De Mouzon, J.; Nygren, K.G.; Zegers-Hochschild, F.; Mansour, R.; Ishihara, O.; Banker, M.; Adamson, G.D. International committee for monitoring assisted reproductive technologies world report: Assisted reproductive technology 2008, 2009 and 2010. *Hum. Reprod.* **2016**, *31*, 1588–1609. [[CrossRef](#)] [[PubMed](#)]
2. Calhaz-Jorge, C.; De Geyter, C. h; Kupka, M.S.; Wyns, C.; Mocanu, E.; Motrenko, T.; Scaravelli, G.; Smeenk, J.; Vidakovic, S.; Goossens, V. Survey on ART and IUI: Legislation, regulation, funding and registries in European countries. *Hum. Reprod. Open* **2020**, *2020*, hoz044. [[CrossRef](#)] [[PubMed](#)]
3. Farquhar, C.; Marjoribanks, J. Assisted reproductive technology: An overview of Cochrane Reviews. *Cochrane Database Syst. Rev.* **2018**, *8*, CD010537. [[CrossRef](#)] [[PubMed](#)]
4. Kushnir, V.A.; Barad, D.H.; Albertini, D.F.; Darmon, S.K.; Gleicher, N. Systematic review of worldwide trends in assisted reproductive technology 2004–2013. *Reprod. Biol. Endocrinol.* **2017**, *15*, 6. [[CrossRef](#)] [[PubMed](#)]
5. Barker, D.J. The developmental origins of chronic adult disease. *Acta Paediatr. Suppl.* **2004**, *93*, 26–33. [[CrossRef](#)]
6. Eriksson, J.G.; Forsén, T.J.; Kajantie, E.; Osmond, C.; Barker, D.J.P. Childhood growth and hypertension in later life. *Hypertension* **2007**, *49*, 1415–1421. [[CrossRef](#)] [[PubMed](#)]
7. Barker, D.J.P.; Osmond, C.; Forsén, T.J.; Kajantie, E.; Eriksson, J.G. Trajectories of growth among children who have coronary events as adults. *N. Engl. J. Med.* **2005**, *353*, 1802–1809. [[CrossRef](#)]
8. Hales, C.N.; Barker, D.J.P.; Clark, P.M.S.; Cox, L.J.; Fall, C.; Osmond, C.; Winter, P.D. Fetal and infant growth and impaired glucose tolerance at age 64. *Br. Med. J.* **1991**, *303*, 1019–1022. [[CrossRef](#)]

9. Yu, H.; Yang, Q.; Sun, X.; Chen, G.; Qian, N.; Cai, R.; Guo, H.; Wang, C. Association of birth defects with the mode of assisted reproductive technology in a Chinese data-linkage cohort. *Fertil. Steril.* **2018**, *109*, 849–856. [[CrossRef](#)]
10. Uk, A.; Collardeau-Frachon, S.; Scanvion, Q.; Michon, L.; Amar, E. Assisted Reproductive Technologies and imprinting disorders: Results of a study from a French congenital malformations registry. *Eur. J. Med. Genet.* **2018**, *61*, 518–523. [[CrossRef](#)]
11. Jiang, Z.; Wang, Y.; Lin, J.; Xu, J.; Ding, G.; Huang, H. Genetic and epigenetic risks of assisted reproduction. *Best Pract. Res. Clin. Obstet. Gynaecol.* **2017**, *44*, 90–104. [[CrossRef](#)] [[PubMed](#)]
12. Wainstock, T.; Walfisch, A.; Shoham-Vardi, I.; Segal, I.; Harlev, A.; Sergienko, R.; Landau, D.; Sheiner, E. Fertility treatments and pediatric neoplasms of the offspring: Results of a population-based cohort with a median follow-up of 10 years. *Am. J. Obstet. Gynecol.* **2017**, *216*, 314. [[CrossRef](#)] [[PubMed](#)]
13. Reigstad, M.M.; Larsen, I.K.; Myklebust, T.Å.; Røsbjærg, T.E.; Oldereid, N.B.; Brinton, L.A.; Storeng, R. Risk of cancer in children conceived by assisted reproductive technology. *Pediatrics* **2016**, *137*, e20152061. [[CrossRef](#)]
14. Fleming, T.P.; Watkins, A.J.; Velazquez, M.A.; Mathers, J.C.; Prentice, A.M.; Stephenson, J.; Barker, M.; Saffery, R.; Yajnik, C.S.; Eckert, J.J.; et al. Origins of lifetime health around the time of conception: Causes and consequences. *Lancet* **2018**, *391*, 1842–1852. [[CrossRef](#)]
15. Cadenas, E.; Packer, L.; Traber, M.G. Antioxidants, oxidants, and redox impacts on cell function—A tribute to Helmut Sies. *Arch. Biochem. Biophys.* **2016**, *595*, 94–99. [[CrossRef](#)]
16. Covarrubias, L.; Hernández-García, D.; Schnabel, D.; Salas-Vidal, E.; Castro-Obregón, S. Function of reactive oxygen species during animal development: Passive or active? *Dev. Biol.* **2008**, *320*, 1–11. [[CrossRef](#)] [[PubMed](#)]
17. Aitken, R.J.; De Iuliis, G.N.; Drevet, J.R. *Oxidants, Antioxidants and Impact of the Oxidative Status in Male Reproduction*; Academic Press: Cambridge, MA, USA, 2019; pp. 91–100.
18. Tremellen, K. *Oxidants, Antioxidants and Impact of the Oxidative Status in Male Reproduction*; Academic Press: Cambridge, MA, USA, 2019; pp. 225–235.
19. Aitken, R.J.; Muscio, L.; Whiting, S.; Connaughton, H.S.; Fraser, B.A.; Nixon, B.; Smith, N.D.; De Iuliis, G.N. Analysis of the effects of polyphenols on human spermatozoa reveals unexpected impacts on mitochondrial membrane potential, oxidative stress and DNA integrity; implications for assisted reproductive technology. *Biochem. Pharmacol.* **2016**, *121*, 78–96. [[CrossRef](#)]
20. Agarwal, A.; Said, T.M.; Bedaiwy, M.A.; Banerjee, J.; Alvarez, J.G. Oxidative stress in an assisted reproductive techniques setting. *Fertil. Steril.* **2006**, *86*, 503–512. [[CrossRef](#)]
21. Gupta, S.; Sekhon, L.; Kim, Y.; Agarwal, A. The Role of Oxidative Stress and Antioxidants in Assisted Reproduction. *Curr. Women's Health Rev.* **2010**, *6*, 227–238. [[CrossRef](#)]
22. Sartori, C.; Rimoldi, S.F.; Rexhaj, E.; Allemann, Y.; Scherrer, U. *Hypoxia*; Springer: New York, NY, USA, 2016; pp. 55–62.
23. Agarwal, A.; Gupta, S.; Sharma, R.K. Role of oxidative stress in female reproduction. *Reprod. Biol. Endocrinol.* **2005**, *3*, 28. [[CrossRef](#)]
24. Muoio, D.M.; Newgard, C.B. Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and β -cell failure in type 2 diabetes. *Nat. Rev. Mol. Cell Biol.* **2008**, *9*, 193–205. [[CrossRef](#)]
25. Ho, E.; Karimi Galougahi, K.; Liu, C.C.; Bhindi, R.; Figtree, G.A. Biological markers of oxidative stress: Applications to cardiovascular research and practice. *Redox Biol.* **2013**, *1*, 483–491. [[CrossRef](#)] [[PubMed](#)]
26. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature* **2006**, *443*, 787–795. [[CrossRef](#)] [[PubMed](#)]
27. Jacob, K.D.; Noren Hooten, N.; Trzeciak, A.R.; Evans, M.K. Markers of oxidant stress that are clinically relevant in aging and age-related disease. *Mech. Ageing Dev.* **2013**, *134*, 139–157. [[CrossRef](#)] [[PubMed](#)]
28. Mahfouz, R.; Sharma, R.; Thiyagarajan, A.; Kale, V.; Gupta, S.; Sabanegh, E.; Agarwal, A. Semen characteristics and sperm DNA fragmentation in infertile men with low and high levels of seminal reactive oxygen species. *Fertil. Steril.* **2010**, *94*, 2141–2146. [[CrossRef](#)] [[PubMed](#)]
29. Allamaneni, S.S.R.; Naughton, C.K.; Sharma, R.K.; Thomas, A.J.; Agarwal, A. Increased seminal reactive oxygen species levels in patients with varicoceles correlate with varicocele grade but not with testis size. *Fertil. Steril.* **2004**, *82*, 1684–1686. [[CrossRef](#)]
30. Biçer, Ş.; Gürsul, C.; Sayar, İ.; Akman, O.; Çakarlı, S.; Aydın, M. Role of ozone therapy in preventing testicular damage in an experimental cryptorchid rat model. *Med. Sci. Monit.* **2018**, *24*, 5832–5839. [[CrossRef](#)]

31. Guimarães, S.B.; Aragão, A.A.; Santos, J.M.V.; Kimura, O.D.S.; Barbosa, P.H.U.; De Vasconcelos, P.R.L. Oxidative stress induced by torsion of the spermatic cord in young rats. *Acta Cir. Bras.* **2007**, *22*, 30–33. [[CrossRef](#)]
32. La Vignera, S.; Condorelli, R.; D'Agata, R.; Vicari, E.; Calogero, A.E. Semen alterations and flow-citometry evaluation in patients with male accessory gland infections. *J. Endocrinol. Investig.* **2012**, *35*, 219–223. [[CrossRef](#)]
33. Tremellen, K. Oxidative stress and male infertility—A clinical perspective. *Hum. Reprod. Update* **2008**, *14*, 243–258. [[CrossRef](#)]
34. Pearce, K.L.; Hill, A.; Tremellen, K.P. Obesity related metabolic endotoxemia is associated with oxidative stress and impaired sperm DNA integrity. *Basic Clin. Androl.* **2019**, *29*, 1–9. [[CrossRef](#)] [[PubMed](#)]
35. Pereira, R.; Sá, R.; Barros, A.; Sousa, M. Major regulatory mechanisms involved in sperm motility. *Asian J. Androl.* **2017**, *19*, 5–14. [[CrossRef](#)] [[PubMed](#)]
36. Pasqualotto, F.F.; Sharma, R.K.; Pasqualotto, E.B.; Agarwal, A. Poor semen quality and ROS-TAC scores in patients with idiopathic infertility. *Urol. Int.* **2008**, *81*, 263–270. [[CrossRef](#)] [[PubMed](#)]
37. Sikka, S.C. Oxidative stress and role of antioxidants in normal and abnormal sperm function. *Front. Biosci.* **1996**, *1*, e78–e86. [[CrossRef](#)]
38. Agarwal, A.; Parekh, N.; Selvam, M.K.P.; Henkel, R.; Shah, R.; Homa, S.T.; Ramasamy, R.; Ko, E.; Tremellen, K.; Esteves, S.; et al. Male Oxidative Stress Infertility (MOSI): Proposed Terminology and Clinical Practice Guidelines for Management of Idiopathic Male Infertility. *World J. Mens Health* **2019**, *37*, 296–312. [[CrossRef](#)]
39. Marchetti, C. Study of mitochondrial membrane potential, reactive oxygen species, DNA fragmentation and cell viability by flow cytometry in human sperm. *Hum. Reprod.* **2002**, *17*, 1257–1265. [[CrossRef](#)]
40. Plante, M.; De Lamirande, E.; Gagnon, C. Reactive oxygen species released by activated neutrophils, but not by deficient spermatozoa, are sufficient to affect normal sperm motility. *Fertil. Steril.* **1994**, *62*, 387–393. [[CrossRef](#)]
41. Sela, S.; Mazor, R.; Amsalam, M.; Yagil, C.; Yagil, Y.; Kristal, B. Primed polymorphonuclear leukocytes, oxidative stress, and inflammation antecede hypertension in the Sabra rat. *Hypertension* **2004**, *44*, 764–769. [[CrossRef](#)]
42. Alvarez, J.G.; Storey, B.T. Differential incorporation of fatty acids into and peroxidative loss of fatty acids from phospholipids of human spermatozoa. *Mol. Reprod. Dev.* **1995**, *42*, 334–346. [[CrossRef](#)]
43. Cannarella, R.; Calogero, A.E.; Condorelli, R.A.; Giaccone, F.; Mongioi, L.M.; La Vignera, S. Non-hormonal treatment for male infertility: The potential role of *Serenoa repens*, selenium and lycopene. *Eur. Rev. Med. Pharmacol. Sci.* **2019**, *23*, 3112–3120. [[CrossRef](#)]
44. Agarwal, A.; Plessis, S.S.D.; Durairajanayagam, D.; Virk, G. *Strategies to Ameliorate Oxidative Stress during Assisted Reproduction*; Springer: Berlin/Heidelberg, Germany, 2014; p. 7.
45. Bisht, S.; Faiq, M.; Tolahunase, M.; Dada, R. Oxidative stress and male infertility. *Nat. Rev. Urol.* **2017**, *14*, 470–485. [[CrossRef](#)] [[PubMed](#)]
46. Benchaib, M.; Braun, V.; Lornage, J.; Hadj, S.; Salle, B.; Lejeune, H.; Guérin, J.F. Sperm DNA fragmentation decreases the pregnancy rate in an assisted reproductive technique. *Hum. Reprod.* **2003**, *18*, 1023–1028. [[CrossRef](#)] [[PubMed](#)]
47. Saleh, R.A.; Agarwal, A.; Sharma, R.K.; Nelson, D.R.; Thomas, A.J. Effect of cigarette smoking on levels of seminal oxidative stress in infertile men: A prospective study. *Fertil. Steril.* **2002**, *78*, 491–499. [[CrossRef](#)]
48. Aboulmaouahib, S.; Madkour, A.; Kaarouch, I.; Sefrioui, O.; Saadani, B.; Copin, H.; Benkhalifa, M.; Louanjli, N.; Cadi, R. Impact of alcohol and cigarette smoking consumption in male fertility potential: Looks at lipid peroxidation, enzymatic antioxidant activities and sperm DNA damage. *Andrologia* **2018**, *50*, e12926. [[CrossRef](#)] [[PubMed](#)]
49. Eskiocak, S.; Gozen, A.S.; Taskiran, A.; Kilic, A.S.; Eskiocak, M.; Gulen, S. Effect of psychological stress on the L-arginine-nitric oxide pathway and semen quality. *Braz. J. Med. Biol. Res.* **2006**, *39*, 581–588. [[CrossRef](#)]
50. Nudell, D.M.; Monoski, M.M.; Lipshultz, L.I. Common medications and drugs: How they affect male fertility. *Urol. Clin. N. Am.* **2002**, *29*, 965–973. [[CrossRef](#)]
51. Ames, B.N. Micronutrient deficiencies. A major cause of DNA damage. *Ann. N. Y. Acad. Sci.* **1999**, *889*, 87–106. [[CrossRef](#)]
52. Anderson, K.; Nisenblat, V.; Norman, R. Lifestyle factors in people seeking infertility treatment—A review. *Aust. N. Z. J. Obstet. Gynaecol.* **2010**, *50*, 8–20. [[CrossRef](#)]

53. Rubes, J.; Selevan, S.G.; Evenson, D.P.; Zudova, D.; Vozdova, M.; Zudova, Z.; Robbins, W.A.; Perreault, S.D. Episodic air pollution is associated with increased DNA fragmentation in human sperm without other changes in semen quality. *Hum. Reprod.* **2005**, *20*, 2776–2783. [[CrossRef](#)]
54. Zhou, D.D.; Hao, J.L.; Guo, K.M.; Lu, C.W.; Liu, X.D. Sperm quality and DNA damage in men from Jilin Province, China, who are occupationally exposed to ionizing radiation. *Genet. Mol. Res.* **2016**, *15*, 1–7. [[CrossRef](#)]
55. Pérez-Crespo, M.; Pintado, B.; Gutiérrez-Adán, A. Scrotal heat stress effects on sperm viability, sperm DNA integrity, and the offspring sex ratio in mice. *Mol. Reprod. Dev.* **2008**, *75*, 40–47. [[CrossRef](#)] [[PubMed](#)]
56. Wang, Y.X.; Zeng, Q.; Sun, Y.; You, L.; Wang, P.; Li, M.; Yang, P.; Li, J.; Huang, Z.; Wang, C.; et al. Phthalate exposure in association with serum hormone levels, sperm DNA damage and spermatozoa apoptosis: A cross-sectional study in China. *Environ. Res.* **2016**, *150*, 557–565. [[CrossRef](#)]
57. Xu, D.X.; Shen, H.M.; Zhu, Q.X.; Chua, L.; Wang, Q.N.; Chia, S.E.; Ong, C.N. The associations among semen quality, oxidative DNA damage in human spermatozoa and concentrations of cadmium, lead and selenium in seminal plasma. *Mutat. Res. Genet. Toxicol. Environ. Mutagen.* **2003**, *534*, 155–163. [[CrossRef](#)]
58. Paoli, D.; Pallotti, F.; Lenzi, A.; Lombardo, F. Fatherhood and sperm DNA damage in testicular cancer patients. *Front. Endocrinol. (Lausanne)* **2018**, *9*, 506. [[CrossRef](#)] [[PubMed](#)]
59. Chibber, S.; Farhan, M.; Hassan, I.; Naseem, I. White light-mediated Cu (II)-5FU interaction augments the chemotherapeutic potential of 5-FU: An in vitro study. *Tumor Biol.* **2011**, *32*, 881–892. [[CrossRef](#)] [[PubMed](#)]
60. Pasqualotto, E.B.; Agarwal, A.; Sharma, R.K.; Izzo, V.M.; Pinotti, J.A.; Joshi, N.J.; Rose, B.I. Effect of oxidative stress in follicular fluid on the outcome of assisted reproductive procedures. *Fertil. Steril.* **2004**, *81*, 973–976. [[CrossRef](#)]
61. Bedaiwy, M.A.; Falcone, T.; Mohamed, M.S.; Aleem, A.A.N.; Sharma, R.K.; Worley, S.E.; Thornton, J.; Agarwal, A. Differential growth of human embryos in vitro: Role of reactive oxygen species. *Fertil. Steril.* **2004**, *82*, 593–600. [[CrossRef](#)]
62. Guérin, P.; El Mouatassim, S.; Ménézo, Y. Oxidative stress and protection against reactive oxygen species in the pre-implantation embryo and its surroundings. *Hum. Reprod. Update* **2001**, *7*, 175–189. [[CrossRef](#)]
63. Oral, O.; Kutlu, T.; Aksoy, E.; Fiçicioğlu, C.; Uslu, H.; Tuğrul, S. The effects of oxidative stress on outcomes of assisted reproductive techniques. *J. Assist. Reprod. Genet.* **2006**, *23*, 81–85. [[CrossRef](#)]
64. Chattopadhyay, R.; Ganesh, A.; Samanta, J.; Jana, S.K.; Chakravarty, B.N.; Chaudhury, K. Effect of follicular fluid oxidative stress on meiotic spindle formation in infertile women with polycystic ovarian syndrome. *Gynecol. Obstet. Investig.* **2010**, *69*, 197–202. [[CrossRef](#)]
65. Máté, G.; Bernstein, L.R.; Török, A.L. Endometriosis Is a Cause of Infertility. Does Reactive Oxygen Damage to Gametes and Embryos Play a Key Role in the Pathogenesis of Infertility Caused by Endometriosis? *Front. Endocrinol. (Lausanne)* **2018**, *9*, 725. [[CrossRef](#)] [[PubMed](#)]
66. Zhang, D.; Luo, W.Y.; Liao, H.; Wang, C.F.; Sun, Y. The effects of oxidative stress to PCOS. *Sichuan Da Xue Xue Bao* **2008**, *39*, 421–423. [[PubMed](#)]
67. Bedaiwy, M.A.; Goldberg, J.M.; Falcone, T.; Singh, M.; Nelson, D.; Azab, H.; Wang, X.; Sharma, R. Relationship between oxidative stress and embryotoxicity of hydrosalpingeal fluid. *Hum. Reprod.* **2002**, *17*, 601–604. [[CrossRef](#)] [[PubMed](#)]
68. Qin, J.; Liu, X.; Sheng, X.; Wang, H.; Gao, S. Assisted reproductive technology and the risk of pregnancy-related complications and adverse pregnancy outcomes in singleton pregnancies: A meta-analysis of cohort studies. *Fertil. Steril.* **2016**, *105*, 73–85. [[CrossRef](#)] [[PubMed](#)]
69. Suhag, A.; Berghella, V. Intrauterine Growth Restriction (IUGR): Etiology and Diagnosis. *Curr. Obstet. Gynecol. Rep.* **2013**, *2*, 102–111. [[CrossRef](#)]
70. Agarwal, A.; Aponte-Mellado, A.; Premkumar, B.J.; Shaman, A.; Gupta, S. The effects of oxidative stress on female reproduction: A review. *Reprod. Biol. Endocrinol.* **2012**, *10*, 49. [[CrossRef](#)]
71. Mihalas, B.P.; De Iuliis, G.N.; Redgrove, K.A.; McLaughlin, E.A.; Nixon, B. The lipid peroxidation product 4-hydroxynonenal contributes to oxidative stress-mediated deterioration of the ageing oocyte. *Sci. Rep.* **2017**, *7*, 6247. [[CrossRef](#)]
72. Prasad, S.; Tiwari, M.; Pandey, A.N.; Shrivastav, T.G.; Chaube, S.K. Impact of stress on oocyte quality and reproductive outcome. *J. Biomed. Sci.* **2016**, *23*, 36. [[CrossRef](#)]

73. Cecchino, G.N.; Seli, E.; Alves da Motta, E.L.; García-Velasco, J.A. The role of mitochondrial activity in female fertility and assisted reproductive technologies: Overview and current insights. *Reprod. Biomed. Online* **2018**, *36*, 686–697. [[CrossRef](#)]
74. Gudmundsdottir, S.L.; Flanders, W.D.; Augestad, L.B. Physical activity and fertility in women: The North-Trøndelag Health Study. *Hum. Reprod.* **2009**, *24*, 3196–3204. [[CrossRef](#)]
75. Abir, R.; Nitke, S.; Ben-Haroush, A.; Fisch, B. In vitro maturation of human primordial ovarian follicles: Clinical significance, progress in mammals, and methods for growth evaluation. *Histol. Histopathol.* **2006**, *21*, 887–898. [[CrossRef](#)] [[PubMed](#)]
76. Conklin, K.A. Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. *Integr. Cancer Ther.* **2004**, *3*, 294–300. [[CrossRef](#)] [[PubMed](#)]
77. Conforti, A.; Mascia, M.; Cioffi, G.; De Angelis, C.; Coppola, G.; De Rosa, P.; Pivonello, R.; Alviggi, C.; De Placido, G. Air pollution and female fertility: A systematic review of literature. *Reprod. Biol. Endocrinol.* **2018**, *16*, 117. [[CrossRef](#)] [[PubMed](#)]
78. Ruder, E.H.; Hartman, T.J.; Blumberg, J.; Goldman, M.B. Oxidative stress and antioxidants: Exposure and impact on female fertility. *Hum. Reprod. Update* **2008**, *14*, 345–357. [[CrossRef](#)] [[PubMed](#)]
79. Zribi, N.; Feki Chakroun, N.; El Euch, H.; Gargouri, J.; Bahloul, A.; Ammar Keskes, L. Effects of cryopreservation on human sperm deoxyribonucleic acid integrity. *Fertil. Steril.* **2010**, *93*, 159–166. [[CrossRef](#)]
80. Gualtieri, R.; Iaccarino, M.; Mollo, V.; Prisco, M.; Iaccarino, S.; Talevi, R. Slow cooling of human oocytes: Ultrastructural injuries and apoptotic status. *Fertil. Steril.* **2009**, *91*, 1023–1034. [[CrossRef](#)]
81. Saeed, Z.; Ali, T.; Hadi, H. Amending in vitro culture condition to overcome oxidative stress in assisted reproduction techniques (ART). *J. Paramed. Sci.* **2015**, *6*, 2. [[CrossRef](#)]
82. Shahar, S.; Wiser, A.; Ickowicz, D.; Lubart, R.; Shulman, A.; Breitbart, H. Light-mediated activation reveals a key role for protein kinase A and sarcoma protein kinase in the development of sperm hyper-activated motility. *Hum. Reprod.* **2011**, *26*, 2274–2282. [[CrossRef](#)]
83. Will, M.A.; Clark, N.A.; Swain, J.E. Biological pH buffers in IVF: Help or hindrance to success. *J. Assist. Reprod. Genet.* **2011**, *28*, 711–724. [[CrossRef](#)]
84. Larkindale, J.; Knight, M.R. Protection against heat stress-induced oxidative damage in Arabidopsis involves calcium, abscisic acid, ethylene, and salicylic acid. *Plant Physiol.* **2002**, *128*, 682–695. [[CrossRef](#)]
85. Bontekoe, S.; Mantikou, E.; van Wely, M.; Seshadri, S.; Repping, S.; Mastenbroek, S. Low oxygen concentrations for embryo culture in assisted reproductive technologies. *Cochrane Database Syst. Rev.* **2012**, *11*, CD008950. [[CrossRef](#)] [[PubMed](#)]
86. Lampiao, F.; Strijdom, H.; Plessis, S. d. Effects of sperm processing techniques involving centrifugation on nitric oxide, reactive oxygen species generation and sperm function. *Open Androl. J.* **2010**, *2*, 1–5. [[CrossRef](#)]
87. Calzi, F.; Papaleo, E.; Rabellotti, E.; Ottolina, J.; Vailati, S.; Viganò, P.; Candiani, M. Exposure of embryos to oxygen at low concentration in a cleavage stage transfer program: Reproductive outcomes in a time-series analysis. *Clin. Lab.* **2012**, *58*, 997–1003. [[CrossRef](#)]
88. Cohen, J.; Gilligan, A.; Esposito, W.; Schimmel, T.; Dale, B. Ambient air and its potential effects on conception in vitro. *Hum. Reprod.* **1997**, *12*, 1742–1749. [[CrossRef](#)] [[PubMed](#)]
89. Agarwal, A.; Durairajanayagam, D.; du Plessis, S.S. Utility of antioxidants during assisted reproductive techniques: An evidence based review. *Reprod. Biol. Endocrinol.* **2014**, *12*, 112. [[CrossRef](#)] [[PubMed](#)]
90. Peritore, A.F.; Siracusa, R.; Crupi, R.; Cuzzocrea, S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. *Nutrients* **2019**, *11*, 2175. [[CrossRef](#)]
91. Halliwell, B.; Gutteridge, J.M.C. *Oxidants, Free Radicals in Biology and Medicine*; Oxford University Press: Oxford, UK, 2015; p. 34.
92. Tan, D.Q.; Suda, T. Reactive Oxygen Species and Mitochondrial Homeostasis as Regulators of Stem Cell Fate and Function. *Antioxid. Redox Signal.* **2018**, *29*, 149–168. [[CrossRef](#)]
93. Ekstrand, M.; Trajkovska, M.G.; Perman-Sundelin, J.; Fogelstrand, P.; Adiels, M.; Johansson, M.; Mattsson-Hultén, L.; Borén, J.; Levin, M. Imaging of intracellular and extracellular ROS levels in atherosclerotic mouse aortas ex vivo: Effects of lipid lowering by diet or atorvastatin. *PLoS ONE* **2015**, *10*, e0130898. [[CrossRef](#)]
94. Rinaldi, M.; Ceciliani, F.; Lecchi, C.; Moroni, P.; Bannerman, D.D. Differential effects of α 1-acid glycoprotein on bovine neutrophil respiratory burst activity and IL-8 production. *Vet. Immunol. Immunopathol.* **2008**, *126*, 199–210. [[CrossRef](#)]

95. Khandrika, L.; Kumar, B.; Koul, S.; Maroni, P.; Koul, H.K. Oxidative stress in prostate cancer. *Cancer Lett.* **2009**, *282*, 125–136. [[CrossRef](#)]
96. Lenaz, G. The mitochondrial production of reactive oxygen species: Mechanisms and implications in human pathology. *IUBMB Life* **2001**, *52*, 159–164. [[CrossRef](#)] [[PubMed](#)]
97. Martín-Romero, F.J.; Miguel-Lasobras, E.M.; Domínguez-Arroyo, J.A.; González-Carrera, E.; Álvarez, I.S. Contribution of culture media to oxidative stress and its effect on human oocytes. *Reprod. Biomed. Online* **2008**, *17*, 652–661. [[CrossRef](#)]
98. Vundru, S.S.; Prasad, N.; Patel, R.; Rani, V.; Yadav, U.C.S. *Free Radicals in Human Health and Disease*; Springer: Berlin/Heidelberg, Germany, 2015; p. 76.
99. Guo, Y.; Yu, S.; Zhang, C.; Kong, A.N.T. Epigenetic regulation of Keap1-Nrf2 signaling. *Free Radic. Biol. Med.* **2015**, *88*, 337–349. [[CrossRef](#)] [[PubMed](#)]
100. Bavineni, M.; Wassenaar, T.M.; Agnihotri, K.; Ussery, D.W.; Lüscher, T.F.; Mehta, J.L. Mechanisms linking preterm birth to onset of cardiovascular disease later in adulthood. *Eur. Heart J.* **2019**, *40*, 1107–1112. [[CrossRef](#)]
101. Hoeijmakers, L.; Kempe, H.; Verschure, P.J. Epigenetic imprinting during assisted reproductive technologies: The effect of temporal and cumulative fluctuations in methionine cycling on the DNA methylation state. *Mol. Reprod. Dev.* **2016**, *83*, 94–107. [[CrossRef](#)]
102. Mayneris-Perxachs, J.; Lima, A.A.; Guerrant, R.L.; Leite Á, M.; Moura, A.F.; Lima, N.L.; Swann, J.R. Urinary N-methylnicotinamide and β -aminoisobutyric acid predict catch-up growth in undernourished Brazilian children. *Sci. Rep.* **2016**, *6*, 19780. [[CrossRef](#)]
103. Kindsfather, A.J.; Czekalski, M.A.; Pressimone, C.A.; Erisman, M.P.; Mann, M.R.W. Perturbations in imprinted methylation from assisted reproductive technologies but not advanced maternal age in mouse preimplantation embryos. *Clin. Epigenetics* **2019**, *11*, 162. [[CrossRef](#)]
104. Movahed, E.; Soleimani, M.; Hosseini, S.; Akbari Sene, A.; Salehi, M. Aberrant expression of miR-29a/29b and methylation level of mouse embryos after in vitro fertilization and vitrification at two-cell stage. *J. Cell Physiol.* **2019**, *234*, 18942–18950. [[CrossRef](#)]
105. Rexhaj, E.; Bloch, J.; Jayet, P.Y.; Rimoldi, S.F.; Dessen, P.; Mathieu, C.; Tolsa, J.F.; Nicod, P.; Scherrer, U.; Sartori, C. Fetal programming of pulmonary vascular dysfunction in mice: Role of epigenetic mechanisms. *Am. J. Physiol. Heart Circ. Physiol.* **2011**, *301*, H247–H252. [[CrossRef](#)]
106. Kietzmann, T.; Petry, A.; Shvetsova, A.; Gerhold, J.M.; Görlach, A. The epigenetic landscape related to reactive oxygen species formation in the cardiovascular system. *Br. J. Pharmacol.* **2017**, *174*, 1533–1554. [[CrossRef](#)]
107. Booth, M.J.; Ost, T.W.B.; Beraldi, D.; Bell, N.M.; Branco, M.R.; Reik, W.; Balasubramanian, S. Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. *Nat. Protoc.* **2013**, *8*, 1841–1851. [[CrossRef](#)]
108. Madugundu, G.S.; Cadet, J.; Wagner, J.R. Hydroxyl-radical-induced oxidation of 5-methylcytosine in isolated and cellular DNA. *Nucleic Acids Res.* **2014**, *42*, 7450–7460. [[CrossRef](#)] [[PubMed](#)]
109. Branco, M.R.; Ficz, G.; Reik, W. Uncovering the role of 5-hydroxymethylcytosine in the epigenome. *Nat. Rev. Genet.* **2012**, *13*, 7–13. [[CrossRef](#)] [[PubMed](#)]
110. Niu, Y.; Desmarais, T.L.; Tong, Z.; Yao, Y.; Costa, M. Oxidative stress alters global histone modification and DNA methylation. *Free Radic. Biol. Med.* **2015**, *82*, 22–28. [[CrossRef](#)]
111. Tsankova, N.; Renthal, W.; Kumar, A.; Nestler, E.J. Epigenetic regulation in psychiatric disorders. *Nat. Rev. Neurosci.* **2007**, *8*, 355–367. [[CrossRef](#)] [[PubMed](#)]
112. Saenen, N.D.; Martens, D.S.; Neven, K.Y.; Alfano, R.; Bové, H.; Janssen, B.G.; Roels, H.A.; Plusquin, M.; Vrijens, K.; Nawrot, T.S. Air pollution-induced placental alterations: An interplay of oxidative stress, epigenetics, and the aging phenotype? *Clin. Epigenetics* **2019**, *11*, 124. [[CrossRef](#)] [[PubMed](#)]
113. He, J.; Jiang, B.H. Interplay Between Reactive Oxygen Species and MicroRNAs in Cancer. *Curr. Pharmacol. Rep.* **2016**, *2*, 82–90. [[CrossRef](#)]
114. Camici, G.G.; Schiavoni, M.; Francia, P.; Bachschmid, M.; Martin-Padura, I.; Hersberger, M.; Tanner, F.C.; Pelicci, P.G.; Volpe, M.; Anversa, P.; et al. Genetic deletion of p66Shc adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 5217–5222. [[CrossRef](#)]
115. Costantino, S.; Paneni, F.; Viridis, A.; Hussain, S.; Mohammed, S.A.; Capretti, G.; Akhmedov, A.; Dalgaard, K.; Chiandotto, S.; Pospisilik, J.A.; et al. Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66 Shc transcription and vascular oxidative stress in obesity. *Eur. Heart J.* **2019**, *40*, 383–391. [[CrossRef](#)]

116. Shimoyama, Y.; Mitsuda, Y.; Hamajima, N.; Niwa, T. Polymorphisms of Nrf2, an antioxidative gene, are associated with blood pressure in Japanese. *Nagoya J. Med. Sci.* **2014**, *76*, 113–120. [[CrossRef](#)]
117. Satta, S.; Mahmoud, A.M.; Wilkinson, F.L.; Yvonne Alexander, M.; White, S.J. The Role of Nrf2 in Cardiovascular Function and Disease. *Oxid. Med. Cell. Longev.* **2017**, *2017*, 9237263. [[CrossRef](#)] [[PubMed](#)]
118. Czogalla, B.; Kahaly, M.; Mayr, D.; Schmoekel, E.; Niesler, B.; Kolben, T.; Burges, A.; Mahner, S.; Jeschke, U.; Trillsch, F. Interaction of ER α and NRF2 impacts survival in ovarian cancer patients. *Int. J. Mol. Sci.* **2019**, *20*, 112. [[CrossRef](#)] [[PubMed](#)]
119. Luo, M.; Shang, L.; Brooks, M.D.; Jiagge, E.; Zhu, Y.; Buschhaus, J.M.; Conley, S.; Fath, M.A.; Davis, A.; Gheordunescu, E.; et al. Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling. *Cell Metab.* **2018**, *28*, 69–86. [[CrossRef](#)] [[PubMed](#)]
120. Schrier, M.S.; Trivedi, M.S.; Deth, R.C. Redox-related epigenetic mechanisms in glioblastoma: Nuclear factor (erythroid-derived 2)-like 2, cobalamin, and dopamine receptor subtype 4. *Front. Oncol.* **2017**, *7*, 46. [[CrossRef](#)]
121. Cuadrado, A.; Rojo, A.I.; Wells, G.; Hayes, J.D.; Cousin, S.P.; Rumsey, W.L.; Attucks, O.C.; Franklin, S.; Levonen, A.L.; Kensler, T.W.; et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. *Nat. Rev. Drug Discov.* **2019**, *18*, 295–317. [[CrossRef](#)] [[PubMed](#)]
122. Impellizzeri, D.; Siracusa, R.; Cordaro, M.; Crupi, R.; Peritore, A.F.; Gugliandolo, E.; D'Amico, R.; Petrosino, S.; Evangelista, M.; Di Paola, R.; et al. N-Palmitoylethanolamine-oxazoline (PEA-OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion. *Neurobiol. Dis.* **2019**, *125*, 77–91. [[CrossRef](#)]
123. Yu, Q.; Li, X.; Cao, X. Linarin could protect myocardial tissue from the injury of Ischemia-reperfusion through activating Nrf-2. *Biomed. Pharmacother.* **2017**, *90*, 1–7. [[CrossRef](#)]
124. Bonnefont-Rousselot, D. Resveratrol and cardiovascular diseases. *Nutrients* **2016**, *8*, 250. [[CrossRef](#)]
125. Wan, J.; Winn, L.M. In utero-initiated cancer: The role of reactive oxygen species. *Birth Defects Res. Part C Embryo Today Rev.* **2006**, *78*, 326–332. [[CrossRef](#)]
126. Giudice, A.; Arra, C.; Turco, M.C. Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents. *Methods Mol. Biol.* **2010**, *647*, 37–74. [[CrossRef](#)]
127. Amin, A. NRF2 Mediated Oxidative Stress Response Activity During Early In Vitro Bovine Embryo Development. Ph.D. Thesis, Universitäts- und Landesbibliothek Bonn, Bonn, Germany, 2015.
128. Chapple, S.J.; Puszyk, W.M.; Mann, G.E. Keap1-Nrf2 regulated redox signaling in utero: Priming of disease susceptibility in offspring. *Free Radic. Biol. Med.* **2015**, *88*, 212–220. [[CrossRef](#)] [[PubMed](#)]
129. Mann, G.E.; Niehueser-Saran, J.; Watson, A.; Gao, L.; Ishii, T.; de Winter, P.; Siow, R.C. Nrf2/ARE regulated antioxidant gene expression in endothelial and smooth muscle cells in oxidative stress: Implications for atherosclerosis and preeclampsia. *Sheng Li Xue Bao* **2007**, *59*, 117–127. [[PubMed](#)]
130. Kensler, T.W.; Wakabayashi, N.; Biswal, S. Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway. *Annu. Rev. Pharmacol. Toxicol.* **2007**, *47*, 89–116. [[CrossRef](#)] [[PubMed](#)]
131. Hayes, J.D.; Dinkova-Kostova, A.T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. *Trends Biochem. Sci.* **2014**, *39*, 199–218. [[CrossRef](#)] [[PubMed](#)]
132. Kwak, M.K.; Wakabayashi, N.; Itoh, K.; Motohashi, H.; Yamamoto, M.; Kensler, T.W. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway: Identification of novel gene clusters for cell survival. *J. Biol. Chem.* **2003**, *278*, 8135–8145. [[CrossRef](#)] [[PubMed](#)]
133. Macleod, A.K.; McMahon, M.; Plummer, S.M.; Higgins, L.G.; Penning, T.M.; Igarashi, K.; Hayes, J.D. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: Demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. *Carcinogenesis* **2009**, *30*, 1571–1580. [[CrossRef](#)] [[PubMed](#)]
134. Li, J.; Lee, J.M.; Johnson, J.A. Microarray analysis reveals an antioxidant responsive element-driven gene set involved in conferring protection from an oxidative stress-induced apoptosis in IMR-32 cells. *J. Biol. Chem.* **2002**, *277*, 388–394. [[CrossRef](#)]
135. Song, D.; Cheng, Y.; Li, X.; Wang, F.; Lu, Z.; Xiao, X.; Wang, Y. Biogenic Nanoselenium Particles Effectively Attenuate Oxidative Stress-Induced Intestinal Epithelial Barrier Injury by Activating the Nrf2 Antioxidant Pathway. *ACS Appl. Mater. Interfaces* **2017**, *9*, 14724–14740. [[CrossRef](#)]

136. Singh, A.; Rangasamy, T.; Thimmulappa, R.K.; Lee, H.; Osburn, W.O.; Brigelius-Flohé, R.; Kensler, T.W.; Yamamoto, M.; Biswal, S. Glutathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2. *Am. J. Respir. Cell Mol. Biol.* **2006**, *35*, 639–650. [[CrossRef](#)]
137. Cho, H.Y.; Reddy, S.P.; DeBiase, A.; Yamamoto, M.; Kleeberger, S.R. Gene expression profiling of NRF2-mediated protection against oxidative injury. *Free Radic. Biol. Med.* **2005**, *38*, 325–343. [[CrossRef](#)]
138. Okawa, H.; Motohashi, H.; Kobayashi, A.; Aburatani, H.; Kensler, T.W.; Yamamoto, M. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. *Biochem. Biophys. Res. Commun.* **2006**, *339*, 79–88. [[CrossRef](#)] [[PubMed](#)]
139. Banning, A.; Deubel, S.; Kluth, D.; Zhou, Z.; Brigelius-Flohé, R. The GI-GPx Gene Is a Target for Nrf2. *Mol. Cell. Biol.* **2005**, *25*, 4914–4923. [[CrossRef](#)] [[PubMed](#)]
140. Habeos, I.G.; Ziros, P.G.; Chartoumpakis, D.; Psyrogiannis, A.; Kyriazopoulou, V.; Papavassiliou, A.G. Simvastatin activates Keap1/Nrf2 signaling in rat liver. *J. Mol. Med.* **2008**, *86*, 1279–1285. [[CrossRef](#)] [[PubMed](#)]
141. Reisman, S.A.; Yeager, R.L.; Yamamoto, M.; Klaassen, C.D. Increased Nrf2 activation in livers from keap1-knockdown mice Increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. *Toxicol. Sci.* **2009**, *108*, 35–47. [[CrossRef](#)]
142. Rangasamy, T.; Cho, C.Y.; Thimmulappa, R.K.; Zhen, L.; Srisuma, S.S.; Kensler, T.W.; Yamamoto, M.; Petrache, I.; Tudor, R.M.; Biswal, S. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. *J. Clin. Investig.* **2004**, *114*, 1248–1259. [[CrossRef](#)]
143. Thimmulappa, R.K.; Mai, K.H.; Srisuma, S.; Kensler, T.W.; Yamamoto, M.; Biswal, S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. *Cancer Res.* **2002**, *62*, 5196–5203.
144. Yates, M.S.; Kwak, M.K.; Egner, P.A.; Groopman, J.D.; Bodreddigari, S.; Sutter, T.R.; Baumgartner, K.J.; Roebuck, B.D.; Liby, K.T.; Yore, M.M.; et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. *Cancer Res.* **2006**, *66*, 2488–2494. [[CrossRef](#)]
145. Hu, R.; Xu, C.; Shen, G.; Jain, M.R.; Khor, T.O.; Gopalkrishnan, A.; Lin, W.; Reddy, B.; Chan, J.Y.; Kong, A.N.T. Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2(−/−) mice. *Cancer Lett.* **2006**, *243*, 170–192. [[CrossRef](#)]
146. Hayes, J.D.; Dinkova-Kostova, A.T. Epigenetic Control of NRF2-Directed Cellular Antioxidant Status in Dictating Life-Death Decisions. *Mol. Cell* **2017**, *68*, 5–7. [[CrossRef](#)]
147. Chowdhury, I.; Mo, Y.; Gao, L.; Kazi, A.; Fisher, A.B.; Feinstein, S.I. Oxidant stress stimulates expression of the human peroxiredoxin 6 gene by a transcriptional mechanism involving an antioxidant response element. *Free Radic. Biol. Med.* **2009**, *46*, 146–153. [[CrossRef](#)]
148. Mahaffey, C.M.; Zhang, H.; Rinna, A.; Holland, W.; Mack, P.C.; Forman, H.J. Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. *Free Radic. Biol. Med.* **2009**, *46*, 1650–1657. [[CrossRef](#)] [[PubMed](#)]
149. Youle, R.J.; Van Der Blik, A.M. Mitochondrial fission, fusion, and stress. *Science* **2012**, *337*, 1062–1065. [[CrossRef](#)]
150. Rodford, J.L.; Torrens, C.; Siow, R.C.M.; Mann, G.E.; Hanson, M.A.; Clough, G.F. Endothelial dysfunction and reduced antioxidant protection in an animal model of the developmental origins of cardiovascular disease. *J. Physiol.* **2008**, *586*, 4709–4720. [[CrossRef](#)] [[PubMed](#)]
151. Giussani, D.A.; Camm, E.J.; Niu, Y.; Richter, H.G.; Blanco, C.E.; Gottschalk, R.; Blake, E.Z.; Horder, K.A.; Thakor, A.S.; Hansell, J.A.; et al. Developmental programming of cardiovascular dysfunction by prenatal hypoxia and oxidative stress. *PLoS ONE* **2012**, *7*, e31017. [[CrossRef](#)]
152. Do Franco, M.C.P.; Dantas, A.P.V.; Akamine, E.H.; Kawamoto, E.M.; Fortes, Z.B.; Scavone, C.; Tostes, R.C.A.; Carvalho, M.H.C.; Nigro, D. Enhanced oxidative stress as a potential mechanism underlying the programming of hypertension in utero. *J. Cardiovasc. Pharmacol.* **2002**, *40*, 501–509. [[CrossRef](#)] [[PubMed](#)]
153. Da Liao, X.; Wang, L.; Huang, X.; Li, Y.; Dasgupta, C.; Zhang, L. Protective effect of antenatal antioxidant on Nicotine-induced heart ischemia-sensitive phenotype in rat offspring. *PLoS ONE* **2016**, *11*, e0150557. [[CrossRef](#)]
154. Cooke, C.L.M.; Shah, A.; Kirschenman, R.D.; Quon, A.L.; Morton, J.S.; Care, A.S.; Davidge, S.T. Increased susceptibility to cardiovascular disease in offspring born from dams of advanced maternal age. *J. Physiol.* **2018**, *596*, 5807–5821. [[CrossRef](#)]

155. Shah, A.; Cooke, C.L.M.; Kirschenman, R.D.; Quon, A.L.; Morton, J.S.; Care, A.S.; Davidge, S.T. Sex-specific effects of advanced maternal age on cardiovascular function in aged adult rat offspring. *Am. J. Physiol. Heart Circ. Physiol.* **2018**, *315*, H1724–H1734. [[CrossRef](#)]
156. Fox, R.; Kitt, J.; Leeson, P.; Aye, C.Y.L.; Lewandowski, A.J. Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring. *J. Clin. Med.* **2019**, *8*, 1625. [[CrossRef](#)]
157. Tripathi, R.R.; Rifas-Shiman, S.L.; Hawley, N.; Hivert, M.F.; Oken, E. Hypertensive disorders of pregnancy and offspring cardiometabolic health at midchildhood: Project viva findings. *J. Am. Heart Assoc.* **2018**, *7*, e007426. [[CrossRef](#)]
158. Yu, Y.; Arah, O.A.; Liew, Z.; Cnattingius, S.; Olsen, J.; Sørensen, H.T.; Qin, G.; Li, J. Maternal diabetes during pregnancy and early onset of cardiovascular disease in offspring: Population based cohort study with 40 years of follow-up. *BMJ* **2019**, *367*, l6398. [[CrossRef](#)] [[PubMed](#)]
159. Kuo, A.H.; Li, C.; Huber, H.F.; Clarke, G.D.; Nathanielsz, P.W. Intrauterine growth restriction results in persistent vascular mismatch in adulthood. *J. Physiol.* **2018**, *596*, 5777–5790. [[CrossRef](#)] [[PubMed](#)]
160. Wen, S.W.; Leader, A.; White, R.R.; Léveillé, M.C.; Wilkie, V.; Zhou, J.; Walker, M.C. A comprehensive assessment of outcomes in pregnancies conceived by in vitro fertilization/intracytoplasmic sperm injection. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **2010**, *150*, 160–165. [[CrossRef](#)]
161. Liu, H.; Zhang, Y.; Gu, H.T.; Feng, Q.L.; Liu, J.Y.; Zhou, J.; Yan, F. Association between assisted reproductive technology and cardiac alteration at age 5 years. *JAMA Pediatr.* **2015**, *169*, 603–605. [[CrossRef](#)]
162. Meister, T.A.; Rimoldi, S.F.; Soria, R.; von Arx, R.; Messerli, F.H.; Sartori, C.; Scherrer, U.; Rexhaj, E. Association of Assisted Reproductive Technologies with Arterial Hypertension During Adolescence. *J. Am. Coll. Cardiol.* **2018**, *72*, 1267–1274. [[CrossRef](#)] [[PubMed](#)]
163. Von Arx, R.; Allemann, Y.; Sartori, C.; Rexhaj, E.; Cerny, D.; De Marchi, S.F.; Soria, R.; Germond, M.; Scherrer, U.; Rimoldi, S.F. Right ventricular dysfunction in children and adolescents conceived by assisted reproductive technologies. *J. Appl. Physiol.* **2015**, *118*, 1200–1206. [[CrossRef](#)] [[PubMed](#)]
164. Scherrer, U.; Rimoldi, S.F.; Rexhaj, E.; Stuber, T.; Duplain, H.; Garcin, S.; De Marchi, S.F.; Nicod, P.; Germond, M.; Allemann, Y.; et al. Systemic and pulmonary vascular dysfunction in children conceived by assisted reproductive technologies. *Circulation* **2012**, *125*, 1890–1896. [[CrossRef](#)]
165. Juonala, M.; Lewis, S.; McLachlan, R.; Hammarberg, K.; Kennedy, J.; Saffery, R.; McBain, J.; Welsh, L.; Cheung, M.; Doyle, L.W.; et al. American Heart Association ideal cardiovascular health score and subclinical atherosclerosis in 22-35-year-old adults conceived with and without assisted reproductive technologies. *Hum. Reprod.* **2020**, *35*, 232–239. [[CrossRef](#)]
166. Hart, R.; Norman, R.J. The longer-term health outcomes for children born as a result of ivf treatment: Part i-general health outcomes. *Hum. Reprod. Update* **2013**, *19*, 232–243. [[CrossRef](#)]
167. Guo, X.Y.; Liu, X.M.; Jin, L.; Wang, T.T.; Ullah, K.; Sheng, J.Z.; Huang, H.F. Cardiovascular and metabolic profiles of offspring conceived by assisted reproductive technologies: A systematic review and meta-analysis. *Fertil. Steril.* **2017**, *107*, 622–631. [[CrossRef](#)]
168. Vrooman, L.A.; Bartolomei, M.S. Can assisted reproductive technologies cause adult-onset disease?. Evidence from human and mouse. *Reprod. Toxicol.* **2017**, *68*, 72–84. [[CrossRef](#)] [[PubMed](#)]
169. Steptoe, P.C.; Edwards, R.G. Birth after the reimplantation of a human embryo. *Lancet* **1978**, *2*, 366. [[CrossRef](#)]
170. Barandalla, M.; Colleoni, S.; Lazzari, G. Differential response of human embryonic stem and somatic cells to non-cytotoxic hydrogen peroxide exposure: An attempt to model in vitro the effects of oxidative stress on the early embryo. *Cell Dev. Biol.* **2016**, *5*, 177. [[CrossRef](#)] [[PubMed](#)]

